Natural History, Risk Factors, and Management of Patients with Mild GO
Publisher
Springer New York
Reference73 articles.
1. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. Chronology of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(4):426–34.
2. Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Invest. 1988;11(8):615–9.
3. Laurberg P, Berman DC, Bulow Pedersen I, Andersen S, Carle A. Incidence and clinical presentation of moderate to severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab. 2012;97(7):2325–32. Evaluation studies research support, Non-U.S. Gov’t.
4. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–90.
5. Kim JM, LaBree L, Levin L, Feldon SE. The relation of Graves’ ophthalmopathy to circulating thyroid hormone status. Br J Ophthalmol. 2004;88(1):72–4. Research support, Non-U.S. Gov’t research support, U.S. Gov’t, P.H.S.